Repositorio Dspace

Listar por autor "Xicoy, Blanca"

Listar por autor "Xicoy, Blanca"

Ordenar por:Orden:Resultados:

  • AML typical mutations ( CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular 
    Castaño-Diez, Sandra; López-Guerra, Mónica; Zugasti, Inés; Calvo, Xavier; Schulz, Felicitas-Isabel; Avendano, Alejandro; Mora, Elvira; Falantes, José; Azaceta, Gemma; Ibáñez, Maríam; Chen-Liang, Tzu-Hua; Notano, Cristina; Amer, Neus; Palomo, Laura; Pomares, Helena; Vila, Jordi; Bernal-del-Castillo, Teresa; Jiménez-Vicente, Carlos; Esteban, Daniel; Guijarro, Francesca; Álamo, José; Cortés-Bullich, Albert; Torrecillas-Mayayo, Victor; Triguero, Ana; Mont-de-Torres, Lucía; Carcelero, Ester; Cardus, Aina; Germing, Ulrich; Betz, Beate; Rozman, María; Arenillas, Leónor; Zamora, Lurdes; Diez-Campelo, María; Xicoy, Blanca; Esteve, Jordi; Díaz-Bey, Marina (ELSEVIER, 2025-01-14)
    Mutations commonly associated with acute myeloid leukemia (AML), such as CEBPA, FLT3, IDH1/2, and NPM1, are rarely found in chronic myelomonocytic leukemia (CMML), and their prognostic significance in CMML has not been ...
  • Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients 
    Estrada, Natalia; Zamora, Lurdes; Ferrer-Marín, Francisca; Palomo, Laura; García, Olga; Vélez, Patricia; de-la-Fuente, Iris; Sagüés, Miguel; Cabezón, Marta; Cortés, Montserrat; Omar-Vallansot, Rolando; Alicia-Senin-Magan, María; Boque, Concepción; Xicoy, Blanca (MDPI, 2022-10)
    Imatinib is the most common first-line tyrosine kinase inhibitor (TKI) used to treat chronic-phase chronic myeloid leukemia (CP-CML). However, only a proportion of patients achieve major molecular response (MMR), so there ...
  • Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes 
    Tentori, Cristina-Astrid; Gregorio, Caterina; Robin, Marie; Gagelmann, Nico; Gurnari, Carmelo; Ball, Somedeb; Caballero-Berrocal, Juan-Carlos; Lanino, Luca; D'Amico, Saverio; Spreafico, Marta; Maggioni, Giulia; Travaglino, Erica; Sauta, Elisabetta; Meggendorfer, Manja; Zhao, Lin-Pierre; Campagna, Alessia; Savevski, Víctor; Santoro, Armando; Al-Ali, Najla; Sallman, David; Sole, Francesc; García-Manero, Guillermo; Germing, Ulrich; Kroger, Nicolaus; Kordasti, Shahram; Santini, Valeria; Sanz, Guillermo; Kern, Wolfgang; Platzbecker, Uwe; Díez-Campelo, María; Maciejewski, Jaroslaw-P; Ades, Lionel; Fenaux, Pierre; Haferlach, Torsten; Zeidan, Amer-M; Castellani, Gastone; Komrokji, Rami; Ieva, Francesca; Della-Porta, Matteo-Giovanni; Bernardi, Massimo; Di-Grazia, Carmen; Vago, Luca; Rivoli, Giulia; Borin, Lorenza; Chiusolo, Patrizia; Giaccone, Luisa; Voso, María-Teresa; Bewersdorf, Jan-Philipp; Nibourel, Olivier; Díaz-Beya, Marina; Jerez-Cayuela, Andrés; Hernández, Francisca; Velázquez-Kennedy, Kyra; Xicoy, Blanca; Ubezio, Marta; Russo, Antonio; Todisco, Gabriele; Mannina, Daniele; Bramanti, Stefania; Zampini, Matteo; Riva, Elena; Bicchieri, Marilena; Asti, Gianluca; Viviani, Filippo; Buizza, Alessandro; Tinterri, Benedetta; Kubasch, Anne-Sophie; Bacigalupo, Andrea; Raiola, Anna-María; Rambaldi, Alessandro; Passamonti, Francesco; Ciceri, Fabio (Lippincott Williams and Wilkins, 2024)
    PURPOSE: Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes (MDS). Several issues must be considered when evaluating the benefits ...
  • e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response 
    Marce, Silvia; Méndez, Aleix; Xicoy, Blanca; Estrada, Natalia; Cabezón, Marta; Sturla, Antonella-Luciana; Ratia-García, Miriam; Angona, Anna; Amat, Paula; Escribano-Serrat, Silvia; Scalzulli, Emilia; Morgades, Mireia; Senin, Alicia; Hernández-Boluda, Juan-Carlos; Ferrer-Marín, Francisca; Anguita, Eduardo; Cortés, Montserrat; Plensa, Esther; Breccia, Massimo; García-Gutiérrez, Valentín; Zamora, Lurdes (MDPI, 2024-02)
    e13a2 and e14a2 are the most frequent transcript types of the BCR::ABL1 fusion gene in chronic myeloid leukemia (CML). The current goal with tyrosine kinase inhibitors (TKI) is to achieve sustained deep molecular response ...
  • Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib 
    Marce, Silvia; Xicoy, Blanca; García, Olga; Cabezón, Marta; Estrada, Natalia; Vélez, Patricia; Boque, Concepción; Sagüés, Miguel; Angona, Anna; Teruel-Montoya, Raúl; Ferrer-Marín, Francisca; Amat, Paula; Hernández-Boluda, Juan-Carlos; Ibarra, Mariana-M; Anguita, Eduardo; Cortés, Montserrat; Fernández-Ruiz, Andrés; Fontanals, Sandra; Zamora, Lurdes (MDPI, 2021-07)
    The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine-kinase inhibitor (TKI) used to treat CML. Some studies suggest that ...
  • Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis 
    Mosquera-Orgueira, Adrián; Arellano-Rodrigo, Eduardo; Garrote, Marta; Martín, Iván; Pérez-Encinas, Manuel-Mateo; Gómez-Casares, María-Teresa; Hernández-Sánchez, Alberto; Ferrer-Marín, Francisca; Mora, Elvira; Vélez, Patricia; Ayala, Rosa; Angona, Anna; de-las-Heras, Natalia; Magro, Elena; Pérez-Míguez, Carlos; Crucitti, Davide; Mata-Vázquez, María-Isabel; Fox, María-Laura; González-de-Villambrosía, Sonia; Ramírez, María-José; García, Ana; García-Gutiérrez, Valentín; Cáceres, Amparo; Durán, María-Antonia; Senín, María-Alicia; Raya, José-María; González, José-A; Cuevas, Beatriz; Xicoy, Blanca; Nangalia, Jyoti; Hernández-Rivas, Jesús-María; Bellosillo, Beatriz; Álvarez-Larrán, Alberto; Hernández-Boluda, Juan-Carlos (John Wiley And Sons Inc, 2024)
    OBJECTIVE: To analyze the influence of the resting interval after removal of a double-balloon for cervical ripening and oxytocin administration on the time to onset of active labor in singleton pregnancies. METHODS: A ...
  • Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes 
    Mosquera-Orgueira, Adrián; Pérez-Encinas, Manuel-Mateo; Díaz-Varela, Nicolás-A; Mora, Elvira; Díaz-Beya, Marina; Montoro, María-Julia; Pomares, Helena; Ramos, Fernando; Tormo, Mar; Jerez-Cayuela, Andrés; Nomdedeu, Josep-F; de-Miguel-Sánchez, Carlos; Leonor, Arenillas; Carcel, Paula; Cedena, María-Teresa; Xicoy, Blanca; Rivero, Eugenia; del-Orbe-Barreto, Rafael-Andrés; Díez-Campelo, María; Benlloch, Luis-E; Crucitti, Davide; Valcárcel, David (WILEY, 2023-10)
    Myelodysplastic neoplasms (MDS) are a heterogeneous group of hematological stem cell disorders characterized by dysplasia, cytopenias, and increased risk of acute leukemia. As prognosis differs widely between patients, and ...
  • Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis 
    Mosquera-Orgueira, Adrián; Pérez-Encinas, Manuel-Mateo; Hernández-Sánchez, Alberto; González-Martínez, Teresa; Arellano-Rodrigo, Eduardo; Martínez-Elicegui, Javier; Villaverde-Ramiro, Ángela; Raya, José-María; Ayala, Rosa; Ferrer-Marín, Francisca; Fox, María-Laura; Vélez, Patricia; Mora, Elvira; Xicoy, Blanca; Mata-Vázquez, María-Isabel; García-Fortes, María; Angona, Anna; Cuevas, Beatriz; Senin, María-Alicia; Ramírez-Payer, Ángel; Ramírez, María-José; Pérez-López, Raúl; González-de-Villambrosía, Sonia; Martínez-Valverde, Clara; Gómez-Casares, María-Teresa; García-Hernández, Carmen; Gasior, Mercedes; Bellosillo, Beatriz; Steegman, Juan-Luis; Álvarez-Larrán, Alberto; Hernández-Rivas, Jesús-María; Hernández-Boluda, Juan-Carlos (WILEY, 2023-01)
    Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful ...
  • Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model 
    Hernández-Boluda, Juan-Carlos; Pereira, Arturo; Álvarez-Larrán, Alberto; Martín, Ana-África; Benzaquen, Ana; Aguirre, Lourdes; Mora, Elvira; González, Pedro; Mora, Jorge; Dorado, Nieves; Sampol, Antonia; García-Gutiérrez, Valentín; López-Godino, Oriana; Fox, María-Laura; Reguera, Juan-Luis; Pérez-Encinas, Manuel-Mateo; Pascual, María-Jesus; Xicoy, Blanca; Parody, Rocío; González-Pinedo, Leslie; Español, Ignacio; Avendano, Alejandro; Correa, Juan-Gonzalo; Vallejo, Carlos; Jurado, Manuel; García-Cadenas, Irene; Osorio, Santiago; Durán, María-Antonia; Sánchez-Guijo, Fermín; Cervantes, Francisco; Piñana, José-Luis (ELSEVIER SCIENCE INC, 2020-12)
    Accurate prognostic tools are crucial to assess the risk/benefit ratio of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with myelofibrosis (MF). We aimed to evaluate the performance of the Myelofibrosis ...
  • Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study 
    Pérez-Lamas, Lucía; Segura-Díaz, Adrián; García-Delgado, Regina; Álvarez-Larran, Alberto; Senin, María-Alicia; Mora, Elvira; Fox, María-Laura; Pastor-Galan, Irene; Azaceta, Gemma; Garrido-Paniagua, Sara; Pérez-López, Raúl; Trejos-Carvajal, Diana-Margarita; Angona, Anna; Albo-López, Carmen; Lorente-Alegre, Pablo; Vara, Miriam; Vera-Goni, Juan-Antonio; De-Miguel-Llorente, Dunia; Fernández-Rodríguez, Ángeles; Marín-Sánchez, Alberto; Hernando-Megido, Adriana; Gómez-Casares, María-Teresa; Stuckey, Ruth; Carreno-Tarragona, Gonzalo; De-Las-Heras-Rodríguez, Natalia; Xicoy, Blanca; Pérez-Encinas, Manuel; Mata-Serna, Raquel; Núñez-Martín-Buitrago, Lucía; Ferrer-Marín, Francisca; Amer-Salas, Neus; Guillén-Rienda, Carolina; Velez, Patricia; Lamarca-Eraso, Laura; Martin, Sandra; Luts-Khoroz, Iryna; De-Cabo-López, Erik; Gil, Ángela; Martín-Consuegra-Ramos, Sofia; Marco-de-Lucas, Fernando; Otero-Martínez-Fornes, María-José; Martín-Mateos, María-Luisa; Arquero, Teresa; Cabezudo-Pérez, Elena; López-Gómez, Luis-Antonio; Martínez-Hellin, Ángela; Tejedor-Gutiérrez, Aurelia; Herrera-de-Pablo, Esther; Mata-Vázquez, María-Isabel; Castillo-Valero, Inmaculada; Fernández, María-José; Aguilar, Carlos; Santaliestra, Marta; García-Menchon, Antonio; Navas-Elorza, Begoña; Durán, María-Antonia; Pérez-Sala, María; Hernández-Santamaria, Teresa; Muñoz-Jarreno, María-Ángeles; Dávila-Valls, Julio; Torres-Jiménez, Williana; Gonzalvez-Fernández, Joan-Alfons; Torres-Mantilla, Hugo-Alexander; Cobo-Rodríguez, Teresa; Abuin-Blanco, Aitor; Pérez, Francisco; Osorio-Prendes, Santiago; Beneit-Villena, Paola; Peralta, Raisa; Herrera, Federico; Canamero-Giro, Eloi; Jiménez-Barcenas, Reyes; Gasior-Kabat, Mercedes; González-de-Villambrosia, Sonia; Tercero-Mora-Rodríguez, Mariana-Teresa; Menéndez-Cuevas, Marina; Cuevas-Ruiz, Beatriz; Fonseca-Santos, Marta; Garces-Piquer, Sonia; de-la-Puerta, Rosalía; Lorenzo-Vizcaya, Álvaro; Hernández-Boluda, Juan-Carlos; García-Gutiérrez, Valentín (SPRINGERNATURE, 2025-04-17)
  • Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD 
    Vilorio-Marqués, Laura; Fernández, Christelle-Castanon; Mora, Elvira; Gutiérrez, Lorena; Rey-Bua, Beatriz; Jiménez-Lorenzo, María-José; Díaz-Beya, Marina; Vara-Pampliega, Miriam; Molero, Antonieta; Sánchez-García, Joaquín; Calabuig, Marisa; Cedena, María-Teresa; Chen-Liang, Tzu-Hua; Díaz-Santa, Johana-Alejandra; Padilla, Irene; Hernández, Francisca; Díez, Rosana; Asensi, Pedro; Xicoy, Blanca; Sanz, Guillermo; Valcárcel, David; Díez-Campelo, María; Bernal, Teresa (SAGE PUBLICATIONS LTD, 2022-09)
    BACKGROUND: The consequences of infectious toxicity of hypomethylating agents (HMAs) on overall survival (OS) of patients diagnosed with high-risk myeloid neoplasms have not been thoroughly investigated. OBJECTIVES: We ...
  • ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options 
    Kiladjian, Jean-Jacques; Ferrer-Marín, Francisca; Al-Ali, Haifa-Kathrin; Álvarez-Larrán, Alberto; Beggiato, Eloise; Bieniaszewska, María; Breccia, Massimo; Buxhofer-Ausch, Veronika; Cerna, Olga; Crisan, Ana-Manuela; Danaila, Catalin-Doru; de-Stefano, Valerio; Doehner, Konstanze; Empson, Victoria; Gora-Tybor, Joanna; Griesshammer, Martín; Grosicki, Sebastián; Guglielmelli, Paola; García-Gutiérrez, Valentín; Heidel, Florian-H; Illes, Arpad; Tomuleasa, Ciprian; James, Chloe; Koschmieder, Steffen; Krauth, María-Theresa; Krejcy, Kurt; Lázaroiu, Mihaela-Cornelia; Mayer, Jiri; Nagy, Zsolt-Gyoergy; Nicolini, Franck-Emmanuel; Palandri, Francesca; Pappa, Vassiliki; Reiter, Andreas-Johannes; Sacha, Tomász; Schlager, Stefanie; Schmidt, Stefan; Terpos, Evangelos; Unger, Martín; Woelfler, Albert; Xicoy, Blanca; Klade, Christoph (Springer, 2024-07)
    Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim ...
  • Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice 
    García-Gutiérrez, Valentín; Luna, Alejandro; Alonso-Domínguez, Juan-Manuel; Estrada, Natalia; Boque, Concepción; Xicoy, Blanca; Giraldo, Pilar; Angona, Anna; Álvarez-Larrán, Alberto; Sánchez-Guijo, Fermín; Ramírez, María-José; Mora, Elvira; Vélez, Patricia; Rosell, Ana; Colorado-Araujo, Mercedes; Cuevas, Beatriz; Sagüés, Miguel; Cortés, Montserrat; Pérez-Encinas, Manuel-Mateo; Casado-Montero, Luis-Felipe; Moreno-Vega, Melania; Serrano, Luis; Gómez, Valle; García-Hernández, Carmen; Lakhwani, Sunil; Paz-Coll, Antonio; de-Paz, Raquel; Suárez-Varela, Sara; Fernández-Ruiz, Andrés; Pérez-López, Raúl; Ortiz-Fernández, Almudena; Jiménez-Velasco, Antonio; Steegmann-Olmedillas, Juan-Luis; Hernández-Boluda, Juan-Carlos (Springer Nature, 2021)
  • Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome 
    Hoeks, Marlijn; Bagguley, Tim; van-Marrewijk, Corine; Smith, Alex; Bowen, David; Culligan, Dominic; Kolade, Seye; Symeonidis, Argiris; Garelius, Hege; Spanoudakis, Michail; Langemeijer, Saskia; Roelofs, Rian; Wiegerinck, Erwin; Tatic, Aurelia; Killick, Sally; Panagiotidis, Panagiotis; Stanca, Oana; Hellström-Lindberg, Eva; Cermak, Jaroslav; van-der-Klauw, Melanie; Wouters, Hanneke; van-Kraaij, Marian; Blijlevens, Nicole; Swinkels, Dorine-W; de-Witte, Theo; Stauder, R; Walder, A; Pfeilstöcker, M; Schoenmetzler-Makrai, A; Burgstaller, S; Thaler, J; Mandac-Rogulj, I; Krejci, M; Voglova, J; Rohon, P; Jonasova, A; Mikulenkova, D; Hochova, I; Jensen, PD; Holm, MS; Kjeldsen, L; Dufva, IH; Vestergaard, H; Re, D; Slama, B; Fenaux, P; Choufi, B; Cheze, S; Klepping, D; Salles, B; de-Renzis, B; Willems, L; de-Prost, D; Gutnecht, J; Courby, S; Siguret, V; Tertian, G; Pascal, L; Chaury, M; Wattel, E; Guerci, A; Legros, L; Itzykson, R; Ades, L; Isnard, F; Sanhes, L; Benramdane, R; Stamatoullas, A; Amé, S; Beyne-Rauzy, O; Gyan, E; Platzbecker, U; Badrakan, C; Germing, U; Lübbert, M; Schlenk, R; Kotsianidis, I; Tsatalas, C; Pappa, V; Galánopoulos, A; Michali, E; Panagiotidis, P; Viniou, N; Katsigiannis, A; Roussou, P; Terpos, E; Kostourou, A; Kartasis, Z; Pouli, A; Palla, K; Briasoulis, V; Hatzimichael, E; Vassilopoulos, G; Kourakli, A; Zikos, P; Anagnostopoulos, A; Kotsopoulou, M; Megalakaki, K; Protopapa, M; Vlachaki, E; Konstantinidou, P; Stemer, G; Nemetz, A; Gotwin, U; Cohen, O; Koren, M; Levy, E; Greenbaum, U; Gino-Moor, S; Price, M; Ofran, Y; Winder, A; Goldshmidt, N; Elias, S; Sabag, R; Hellman, I; Ellis, M; Braester, A; Rosenbaum, H; Berdichevsky, S; Itzhaki, G; Wolaj, O; Yeganeh, S; Katz, O; Filanovsky, K; Dali, N; Mittelman, M; Malcovati, L; Fianchi, L; vd-Loosdrecht, A; Matthijssen, V; Herbers, A; Pruijt, H; Aboosy, N; de-Vries, F; Velders, G; Jacobs, E; MacKenzie, M; Lensen, C; Kuijper, P; Madry, K; Cámara, M; Almeida, A; Vulkan, G; Stanca-Ciocan, O; Savic, A; Pedro, C; Xicoy, Blanca; Leiva, P; Muñoz, J; Betes, V; Benavente, C; Lozano, M; Martínez, M; Iniesta, P; Bernal, T; Díez-Campelo, María; Tormo, D; Andreu-Lapiedra, R; Sanz, G; Hesse-Sundin, E; Karlsson, C; Antunovic, P; Jönsson, A; Brandefors, L; Nilsson, L; Kozlowski, P; Grövdal, M; Larsson, K; Wallvik, J; Lorenz, F; Ejerblad, E; Craddock, C; Cahalin, P; Ackroyd, S; Wong, C; Warren, A; Drummond, M; Hall, C; Rothwell, K; Green, S; Ali, S; Karakantza, M; Dennis, M; Jones, G; Parker, J; Bowen, A; Radia, R; Das-Gupta, E; Vyas, P; Nga, E; Creagh, D; Ashcroft, J; Mills, J; Bond, L (Springer Nature, 2021)
  • Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors 
    Pérez-Lamas, Lucía; Luna, Alejandro; Boque, Concepción; Xicoy, Blanca; Giraldo, Pilar; Pérez-López, Raúl; Ruiz-Nuno, Concepción; de-las-Heras, Natalia; Mora-Castera, Elvira; López-Marin, Javier; Segura-Díaz, Adrián; Gómez, Valle; Vélez-Tenza, Patricia; Sierra-Pacho, Magdalena; Vera-Goni, Juan-Antonio; Moreno-Vega, Melania; Álvarez-Larrán, Alberto; Cortés, Montse; Pérez-Encinas, Manuel-Mateo; Carrascosa-Mastell, Patricia; Angona, Anna; Rosell, Ana; Lakhwani, Sunil; Colorado, Mercedes; Ramila, Elena; Cervero, Carlos; Cuevas, Beatriz; Villalón-Blanco, Lucía; de-Paz, Raquel; Paz-Coll, Antonio; Fernández, María-José; Felipe-Casado, Luis; Alonso-Domínguez, Juan-Manuel; Anguita-Arance, María-Magdalena; Salamanca-Cuenca, Araceli; Jiménez-Velasco, Antonio; Osorio-Prendes, Santiago; Santaliestra, Marta; Lis-Chulvi, María-José; Hernández-Boluda, Juan-Carlos; García-Gutiérrez, Valentín (MDPI, 2023-02)
    (1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction of asciminib may be a ...